Annals of Oncology Advance Access originally published online on November 27, 2007
Annals of Oncology 2008 19(4):787-792; doi:10.1093/annonc/mdm548
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
phase I and pharmacokinetics |
Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy
1 Department of Medicine
2 Department of Biostatistics and Epidemiology
3 Department of Radiotherapy
4 Clinical and Translational Research Division, Institut Gustave Roussy, Villejuif
5 Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France
* Correspondence to: Dr J.-C. Soria, Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France. Tel: +33-1-42-11-43-39; Fax: +33-1-42-11-50-38; E-mail: soria{at}igr.fr
Background: The oncology community usually perceives phase I oncology trials as associated with poor or limited benefits and substantial risks. There is scarce data concerning outcome and survival of patients enrolled in current phase I oncology trials.
Patients and methods: We reviewed all phase I oncology trials conducted by investigators from the Adult Phase I Unit at Institut Gustave Roussy from 2003 to 2006. We report data concerning patient demographics, treatment outcome, toxicity, survival and type of care after trial exit.
Results: We analyzed 10 trials involving 180 participants. The overall response rate was 7.2%. Disease control (objective response plus stable disease) was achieved in 48.2% of patients. The rate of toxic death was 0.5%. In all, 38% of patients had at least one episode of grade 3 or 4 toxic events. The median progression-free survival and the median overall survival (OS) were 2.3 and 8.7 months, respectively. On multivariate analysis, a time between diagnosis of disease and inclusion in the phase I trial 
24 months and evidence of disease control were statistically significant predictors of improved OS.
Conclusion: Current phase I oncology trials are safe and are associated with clinical benefit in a substantial proportion of patients.
Key words: anticancer drugs, early clinical trials, oncology, phase I trials, targeted therapies
Received for publication September 25, 2007. Revision received October 29, 2007. Accepted for publication October 30, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H.-T. Arkenau, J. Barriuso, D. Olmos, J. E. Ang, J. de Bono, I. Judson, and S. Kaye Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials J. Clin. Oncol., June 1, 2009; 27(16): 2692 - 2696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-R. Hanauske, M. Lahn, L. C. Musib, K. Weigang-Kohler, E. Yilmaz, T. Graefe, B. Kuenen, D. Thornton, P. McNealy, and G. Giaccone Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer Ann. Onc., June 1, 2009; (2009) mdp049v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G Miller and S. Joffe Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option? Clinical Trials, December 1, 2008; 5(6): 617 - 623. [Abstract] [PDF]
|
|